The United States continues to face a public health emergency of opioid overdoses, the effects of which could be dramatically reduced through increased access to the opioid antagonist naloxone. But naloxone is too often unavailable when and where it is most needed, partly due to its continued status as a prescription medication. Although states and the federal Food and Drug Administration have acted to increase access to naloxone, these changes are insufficient to address this unprecedented crisis. This commentary argues that the Food and Drug Administration should reclassify naloxone from prescription-only to over-the-counter status, a change that could save hundreds if not thousands of lives every year.
Recent Abstracts
Cost-Benefit Analysis for Air Pollution Control Strategies in Jakarta
Key Messages on Alcohol Harms and Policy Solutions
Flooding and Early Childhood Development
RESET Alcohol – Public Attitudes Towards Alcohol Policy in Mexico
Estimating the annual production data of bidi sticks in India using the “back-of-the-envelop”…
Beyond air pollution: a national assessment of cooking-related burns in Ghana
The Olympic game’s up: it’s time for the IOC to stop promoting sugary…
Accelerating the Health Benefits of Scaling Clean Household Energy in India
Childhood Blood Lead Surveillance in Bihar
Future of tobacco marketing: the metaverse, NFTs and the next generation of the…